AIM: To investigate the expression of markers that are correlated with the prognosis of colorectal cancer (CRC) patients. METHODS: One hundred and fifty-six CRC patients were followed up for more than 3 years after radical surgery. Immunohistochemical (IHC) analysis was performed to detect the expression of 14 pathway-related markers (p53, APC, p21ras, E-cadherin, endothelin-B receptor, Shp2, ADCY-2, SPARCL1, neuroligin1, hsp27, mmp-9, MAPK, MSH2 and rho) in specimens from these patients. Bioinformatics analysis involving a Support Vector Machine (SVM) was used to determine the best prognostic model from combinations of these markers. RESULTS: Seven markers (SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK) were significantly related to the prognosis and clinical pathological features of the CRC patients (P < 0.05). Prognostic models were established through SVM from combinations of these 7 markers and proved able to differentiate patients with dissimilar survival, especially in stage II/III patients. According to the best prognostic model, the p53/SPARCL1 model, patients having high p53 and low SPARCL1 expression had about 50% lower 3-year survival than others (P < 0.001). CONCLUSION: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are potential prognostic markers in CRC. A p53/SPARCL1 bioinformatics model may be used as a supplement to tumor-nodes-metastasis staging.
AIM: To investigate the expression of markers that are correlated with the prognosis of colorectal cancer (CRC) patients. METHODS: One hundred and fifty-six CRCpatients were followed up for more than 3 years after radical surgery. Immunohistochemical (IHC) analysis was performed to detect the expression of 14 pathway-related markers (p53, APC, p21ras, E-cadherin, endothelin-B receptor, Shp2, ADCY-2, SPARCL1, neuroligin1, hsp27, mmp-9, MAPK, MSH2 and rho) in specimens from these patients. Bioinformatics analysis involving a Support Vector Machine (SVM) was used to determine the best prognostic model from combinations of these markers. RESULTS: Seven markers (SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK) were significantly related to the prognosis and clinical pathological features of the CRCpatients (P < 0.05). Prognostic models were established through SVM from combinations of these 7 markers and proved able to differentiate patients with dissimilar survival, especially in stage II/III patients. According to the best prognostic model, the p53/SPARCL1 model, patients having high p53 and low SPARCL1 expression had about 50% lower 3-year survival than others (P < 0.001). CONCLUSION:SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are potential prognostic markers in CRC. A p53/SPARCL1 bioinformatics model may be used as a supplement to tumor-nodes-metastasis staging.
Authors: Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Stephen G Swisher; Jack A Roth; Ritsuko Komaki; Jian Gu; J Jack Lee; Marshall Hicks; Jae Y Ro; Waun K Hong; James A Merritt; Kamaran Ahrar; N Edward Atkinson; Arlene M Correa; Marcelo Dolormente; Linda Dreiling; Adel K El-Naggar; Frank Fossella; Rhodette Francisco; Bonnie Glisson; Susan Grammer; Roy Herbst; Armando Huaringa; Bonnie Kemp; Fadlo R Khuri; Jonathan M Kurie; Zhongxio Liao; Timothy J McDonnell; Rudolfo Morice; Frank Morello; Reginald Munden; Vassiliki Papadimitrakopoulou; Katherine M W Pisters; Joe B Putnam; Arcenio J Sarabia; Thomas Shelton; Craig Stevens; Daniel M Shin; William R Smythe; Ara A Vaporciyan; Garrett L Walsh; Min Yin Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Ahmedin Jemal; Limin X Clegg; Elizabeth Ward; Lynn A G Ries; Xiaocheng Wu; Patricia M Jamison; Phyllis A Wingo; Holly L Howe; Robert N Anderson; Brenda K Edwards Journal: Cancer Date: 2004-07-01 Impact factor: 6.860
Authors: Jason M Conley; Cameron S Brand; Amy S Bogard; Evan P S Pratt; Ruqiang Xu; Gregory H Hockerman; Rennolds S Ostrom; Carmen W Dessauer; Val J Watts Journal: J Pharmacol Exp Ther Date: 2013-09-05 Impact factor: 4.030
Authors: Yuzhu Xiang; Qingchao Qiu; Ming Jiang; Renjie Jin; Brian D Lehmann; Douglas W Strand; Bojana Jovanovic; David J DeGraff; Yi Zheng; Dina A Yousif; Christine Q Simmons; Thomas C Case; Jia Yi; Justin M Cates; John Virostko; Xiusheng He; Xunbo Jin; Simon W Hayward; Robert J Matusik; Alfred L George; Yajun Yi Journal: Mol Oncol Date: 2013-07-20 Impact factor: 6.603
Authors: Joanna L Richens; Kelly-Ann Vere; Roger A Light; Daniele Soria; Jonathan Garibaldi; A David Smith; Donald Warden; Gordon Wilcock; Nin Bajaj; Kevin Morgan; Paul O'Shea Journal: Int J Mol Epidemiol Genet Date: 2014-05-29